Safety and Effectiveness of Short-course AmBisome in the Treatment of Post-Kala-azar Dermal Leishmaniasis (PKDL): a Prospective Cohort Study in Bangladesh

Trial Profile

Safety and Effectiveness of Short-course AmBisome in the Treatment of Post-Kala-azar Dermal Leishmaniasis (PKDL): a Prospective Cohort Study in Bangladesh

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs Amphotericin B liposomal (Primary)
  • Indications Visceral leishmaniasis
  • Focus Therapeutic Use
  • Acronyms MSF-PKDL-STUDY
  • Most Recent Events

    • 22 Mar 2018 New trial record
    • 15 Mar 2018 Results assessing safety and efficacy of AmBisome in treatment of Post Kala Azar Dermal Leishmaniasis (PKDL) published in the Clinical Infectious Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top